Walgreens teams up with Alphabet’s Verily to tackle chronic disease
The initial major focus of the partnership will be medication adherence, which costs the U.S. healthcare system nearly $300 billion annually
The initial major focus of the partnership will be medication adherence, which costs the U.S. healthcare system nearly $300 billion annually
A study by the Michael J Fox Foundation using Verily's Study Watch underscores the increasing use of wearables not only for Parkinson's disease research but also to identify ways to more accurately diagnose the neurodegenerative condition and to assess the impact of medication and other types of treatment interventions.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
The tech giant is applying its AI expertise to the medical space. But that's not all — Google has also shown interest in other healthcare topics like interoperability and insurance.
The picks span telecom giants to medtech companies but also include smaller companies with novel technologies such as digital therapeutics developer Pear Therapeutics and Tidepool -- an open source technology developer to support diabetes management, .
Billion-dollar private venture capital rounds are apparently now a "thing." Roivant sealed the deal on Wednesday, following a multi-year trend towards bigger investment rounds in the life sciences.
"[Behavioral health] is a very hot topic now because we have easy access to so much more data thanks to smartphones and wearable sensors," said Dr. John Torous, co-director of the digital psychiatry program at Beth Israel Deaconess Medical Center.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Verily has pulled off a recruitment coup, hiring former FDA Commissioner Robert Califf as a company advisor. It comes at a crucial time as top talent leaves and criticism of CEO Andrew Conrad persists.
Insel, who had headed up an initiative to develop new technologies to address anxiety and depression, has left Verily after less than two years with the life sciences arm of Alphabet.
Verily Life Sciences is partnering with Stanford Medicine and the Duke University School of Medicine to study 10,000 volunteers over four years as part of a new initiative dubbed Project Baseline.
During a HITLAB live streamed discussion at Columbia University Medical Center, Olivier Rabenschlag, head of creative at Google, discussed how the tech giant is impacting the healthcare space.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
More than 650 medical device recalls encompassing 180 million units were registered in the second half of 2016, some of the highest numbers seen this century. It's a poor departure point as a new era in product complexity begins.
Verily, formerly Google Lifesciences recently launched the Liftware Level: a handheld robotic device that compensates for erratic hand and arm movements, allowing people to eat without spilling.
Exactly one hour after Siemens Healthineers announced a deal with IBM Watson Health, 3M Health Information Systems said it was teaming with the Google-affiliated Verily Life Sciences to develop technology to support population health management.
Sanofi and Verily are on an audacious venture with their new startup, Onduo, that seeks to move the needle in diabetes care by addressing behavior change and lifestyle modification in patients.
Brian Otis, CTO of Google's life sciences business, Verily, describes the technology at the heart of the GSK joint venture that seeks to understand and modify the language of the nervous system in patients with different diseases.